Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease
Status:
Terminated
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
This study is designed to address the feasibility of a randomized, double masked, cross-over
study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other
complications of sickle cell disease (SCD).